Literature DB >> 16051864

High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.

Francesca Ceccherini-Silberstein1, Federico Gago, Maria Santoro, Caterina Gori, Valentina Svicher, Fátima Rodríguez-Barrios, Roberta d'Arrigo, Massimo Ciccozzi, Ada Bertoli, Antonella d'Arminio Monforte, Jan Balzarini, Andrea Antinori, Carlo-Federico Perno.   

Abstract

To define the extent of sequence conservation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) in vivo, the first 320 amino acids of RT obtained from 2,236 plasma-derived samples from a well-defined cohort of 1,704 HIV-1-infected individuals (457 drug naïve and 1,247 drug treated) were analyzed and examined in structural terms. In naïve patients, 233 out of these 320 residues (73%) were conserved (<1% variability). The majority of invariant amino acids clustered into defined regions comprising between 5 and 29 consecutive residues. Of the nine longest invariant regions identified, some contained residues and domains critical for enzyme stability and function. In patients treated with RT inhibitors, despite profound drug pressure and the appearance of mutations primarily associated with resistance, 202 amino acids (63%) remained highly conserved and appeared mostly distributed in regions of variable length. This finding suggests that participation of consecutive residues in structural domains is strictly required for cooperative functions and sustainability of HIV-1 RT activity. Besides confirming the conservation of amino acids that are already known to be important for catalytic activity, stability of the heterodimer interface, and/or primer/template binding, the other 62 new invariable residues are now identified and mapped onto the three-dimensional structure of the enzyme. This new knowledge could be of help in the structure-based design of novel resistance-evading drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051864      PMCID: PMC1182657          DOI: 10.1128/JVI.79.16.10718-10729.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  S F Chao; V L Chan; P Juranka; A H Kaplan; R Swanstrom; C A Hutchison
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

2.  Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.

Authors:  C F Perno; A Cozzi-Lepri; C Balotta; F Forbici; M Violin; A Bertoli; G Facchi; P Pezzotti; G Cadeo; G Tositti; S Pasquinucci; S Pauluzzi; A Scalzini; B Salassa; A Vincenti; A N Phillips; F Dianzani; A Appice; G Angarano; L Monno; G Ippolito; M Moroni; A d' Arminio Monforte
Journal:  J Infect Dis       Date:  2001-08-30       Impact factor: 5.226

3.  Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization.

Authors:  M Ghosh; P S Jacques; D W Rodgers; M Ottman; J L Darlix; S F Le Grice
Journal:  Biochemistry       Date:  1996-07-02       Impact factor: 3.162

4.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit.

Authors:  P K Pandey; N Kaushik; T T Talele; P N Yadav; V N Pandey
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

6.  Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation.

Authors:  Carlo Federico Perno; Alessandro Cozzi-Lepri; Claudia Balotta; Ada Bertoli; Michela Violin; Laura Monno; Tiziano Zauli; Maria Montroni; Giuseppe Ippolito; Antonella d'Arminio-Monforte
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

7.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

9.  Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities.

Authors:  Pradeep K Pandey; Neerja Kaushik; Kamalendra Singh; Bechan Sharma; Alok K Upadhyay; Suriender Kumar; Dylan Harris; Virendra N Pandey
Journal:  BMC Biochem       Date:  2002-06-18       Impact factor: 4.059

Review 10.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

View more
  26 in total

1.  Analysis of selection pressure and mutational pattern of HIV type 1 reverse transcriptase region among treated and nontreated patients.

Authors:  Uma Shanmugasundaram; Suniti Solomon; Vidya Madhavan; Murugavel G Kailapuri; Kumarasamy Nagalingeswaran; Sunil Suhas Solomon; Kenneth H Mayer; Balakrishnan Pachamuthu
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-19       Impact factor: 2.205

2.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

3.  Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.

Authors:  Rajin Shahriar; Soo-Yon Rhee; Tommy F Liu; W Jeffrey Fessel; Anthony Scarsella; William Towner; Susan P Holmes; Andrew R Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

4.  Short communication: Nucleotide variation and positively selected sites in HIV type 1 reverse transcriptase among heterosexual transmission pairs.

Authors:  Uma Shanmugasundaram; Suniti Solomon; Kailapuri G Murugavel; Kumarasamy Nagalingeswaran; Sunil S Solomon; Kenneth H Mayer; Balakrishnan Pachamuthu
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

5.  Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.

Authors:  Valentina Svicher; Tobias Sing; Maria Mercedes Santoro; Federica Forbici; Fátima Rodríguez-Barrios; Ada Bertoli; Niko Beerenwinkel; Maria Concetta Bellocchi; Federigo Gago; Antonella d'Arminio Monforte; Andrea Antinori; Thomas Lengauer; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Sunil S Solomon; Rami Kantor; David Katzenstein; Sathasivam Sivamalar; Nagalingeswaran Kumarasamy; Davey M Smith; Kenneth H Mayer; Suniti Solomon; Pachamuthu Balakrishnan
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

7.  Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.

Authors:  Kathleen M Frey; William T Gray; Krasimir A Spasov; Mariela Bollini; Ricardo Gallardo-Macias; William L Jorgensen; Karen S Anderson
Journal:  Chem Biol Drug Des       Date:  2014-03-14       Impact factor: 2.817

8.  Co-lethality studied as an asset against viral drug escape: the HIV protease case.

Authors:  Sophie Brouillet; Thomas Valere; Emmanuelle Ollivier; Laurent Marsan; Anne Vanet
Journal:  Biol Direct       Date:  2010-06-17       Impact factor: 4.540

9.  Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Authors:  Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational Pattern.

Authors:  Xiao-Min Zhang; Qiwei Zhang; Hao Wu; Terrence Chi-Kong Lau; Xuan Liu; Hin Chu; Ke Zhang; Jie Zhou; Zhi-Wei Chen; Dong-Yan Jin; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-09       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.